[go: up one dir, main page]

MX2017001624A - Sal de derivado de piridina monociclico y su cristal. - Google Patents

Sal de derivado de piridina monociclico y su cristal.

Info

Publication number
MX2017001624A
MX2017001624A MX2017001624A MX2017001624A MX2017001624A MX 2017001624 A MX2017001624 A MX 2017001624A MX 2017001624 A MX2017001624 A MX 2017001624A MX 2017001624 A MX2017001624 A MX 2017001624A MX 2017001624 A MX2017001624 A MX 2017001624A
Authority
MX
Mexico
Prior art keywords
salt
crystal
pyridine derivative
monocyclic pyridine
monocyclic
Prior art date
Application number
MX2017001624A
Other languages
English (en)
Other versions
MX369646B (es
Inventor
Yoshida Kenshi
Ozaki Shunsuke
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2017001624A publication Critical patent/MX2017001624A/es
Publication of MX369646B publication Critical patent/MX369646B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona sales que consisten en un ácido organocarboxílico seleccionado entre el grupo que consiste en ácido succínico y ácido maleico y un compuesto representado por medio de la fórmula (I) (ver Fórmula) y sus cristales, que se pueden usar como materiales brutos para sustancias farmacéuticas.
MX2017001624A 2014-08-18 2015-08-17 Sal de derivado de piridina monociclico y su cristal. MX369646B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014166118 2014-08-18
PCT/JP2015/073047 WO2016027781A1 (ja) 2014-08-18 2015-08-17 単環ピリジン誘導体の塩およびその結晶

Publications (2)

Publication Number Publication Date
MX2017001624A true MX2017001624A (es) 2017-04-27
MX369646B MX369646B (es) 2019-11-15

Family

ID=55350725

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001624A MX369646B (es) 2014-08-18 2015-08-17 Sal de derivado de piridina monociclico y su cristal.

Country Status (14)

Country Link
US (1) US9951047B2 (es)
EP (1) EP3184520B1 (es)
JP (1) JP5925978B1 (es)
KR (1) KR102344105B1 (es)
CN (1) CN106660997B (es)
AU (1) AU2015304465B2 (es)
BR (1) BR112017002268B1 (es)
CA (1) CA2956270C (es)
ES (1) ES2914072T3 (es)
IL (1) IL250290B (es)
MX (1) MX369646B (es)
RU (1) RU2658821C1 (es)
SG (1) SG11201700703XA (es)
WO (1) WO2016027781A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6503450B2 (ja) 2015-03-25 2019-04-17 国立研究開発法人国立がん研究センター 胆管癌治療剤
SG10201913213WA (en) 2015-12-17 2020-03-30 Eisai R&D Man Co Ltd Therapeutic agent for breast cancer
RU2020108284A (ru) * 2017-10-12 2021-11-12 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция, содержащая селективный ингибитор тирозинкиназы fgfr
CN111712245A (zh) * 2018-03-28 2020-09-25 卫材R&D管理有限公司 用于肝细胞癌的治疗剂
CN115397415A (zh) 2020-04-17 2022-11-25 卫材R&D管理有限公司 乳腺癌治疗剂
JP7792336B2 (ja) 2020-07-31 2025-12-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
TW202233185A (zh) 2020-10-28 2022-09-01 日商衛材R&D企管股份有限公司 腫瘤治療用醫藥組合物
KR20240052933A (ko) 2021-08-31 2024-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 모노사이클릭 피리딘 유도체를 제조하기 위한 방법
KR20240052932A (ko) 2021-08-31 2024-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 모노사이클릭 피리딘 유도체의 합성 중간체의 제조 방법
CA3244743A1 (en) * 2022-03-18 2025-06-13 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences SALT OF A SIX-LINK AMINO-SUBSTITUTE NITRIC HETEROCYCLIC COMPOUND, CRYSTALLINE FORM THEREIN, CORRESPONDING PREPARATION PROCESS AND ASSOCIATED USE

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN100339376C (zh) 2002-08-30 2007-09-26 卫材R&D管理有限公司 含氮芳环衍生物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
KR20050111636A (ko) 2003-04-10 2005-11-25 에프. 호프만-라 로슈 아게 피리미도 화합물
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
EP2158470A1 (en) 2007-06-25 2010-03-03 Qinetiq Limited Preconcentrator device incorporating a polymer of intrinsic microporosity
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
CL2008003675A1 (es) 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
GEP20125502B (en) 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
AU2009261683A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
US8263610B2 (en) 2008-12-30 2012-09-11 Arqule, Inc. Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
DK2379506T3 (en) 2008-12-30 2015-12-14 Arqule Inc Substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
JP5225470B2 (ja) 2009-08-07 2013-07-03 中外製薬株式会社 アミノピラゾール誘導体
KR20120101367A (ko) 2009-10-30 2012-09-13 노파르티스 아게 3-（2,6-디클로로-3,5-디메톡시-페닐）-1-｛6-［4-（4-에틸-피페라진-1-일）-페닐아미노］-피리미딘-4-일｝-1-메틸-우레아의 ｎ-옥시드
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
HRP20190135T1 (hr) 2011-07-19 2019-03-22 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-yl-benzamidi i 4-imidazotriazin-1-yl-benzamidi kao inhibitori btk
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
EP2657233B1 (en) 2012-01-19 2014-08-27 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
JP5343177B1 (ja) 2012-02-28 2013-11-13 アステラス製薬株式会社 含窒素芳香族へテロ環化合物
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
EP2871236A4 (en) 2012-07-05 2016-03-09 Nat Cancer Ct FGFR2 fusion
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
ES2643571T3 (es) 2012-09-27 2017-11-23 Chugai Seiyaku Kabushiki Kaisha Gen de fusión FGFR3 y fármaco que se dirige al mismo
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
US20170217935A1 (en) 2017-08-03
BR112017002268B1 (pt) 2022-11-08
KR102344105B1 (ko) 2021-12-29
CA2956270A1 (en) 2016-02-25
SG11201700703XA (en) 2017-03-30
RU2658821C1 (ru) 2018-06-25
EP3184520A1 (en) 2017-06-28
AU2015304465B2 (en) 2019-05-09
WO2016027781A1 (ja) 2016-02-25
JP5925978B1 (ja) 2016-05-25
CN106660997A (zh) 2017-05-10
EP3184520B1 (en) 2022-03-23
CN106660997B (zh) 2019-05-21
EP3184520A4 (en) 2018-04-18
IL250290A0 (en) 2017-03-30
AU2015304465A1 (en) 2017-02-23
KR20170035927A (ko) 2017-03-31
MX369646B (es) 2019-11-15
IL250290B (en) 2020-06-30
CA2956270C (en) 2022-08-09
US9951047B2 (en) 2018-04-24
JPWO2016027781A1 (ja) 2017-04-27
BR112017002268A2 (pt) 2017-11-21
ES2914072T3 (es) 2022-06-07

Similar Documents

Publication Publication Date Title
MX2017001624A (es) Sal de derivado de piridina monociclico y su cristal.
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2016044641A3 (en) Carm1 inhibitors and uses thereof
TW201613911A (en) Heterocyclic compounds and uses thereof
WO2015200677A8 (en) Prmt5 inhibitors and uses thereof
EP4071149A3 (en) Heterocyclic compounds and uses thereof
MX378194B (es) Compuestos organicos.
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
PH12016502246B1 (en) Carboxamide derivatives
MX2016014946A (es) Derivados de carboxamida.
EA201691741A1 (ru) Фармацевтическая композиция
PH12016502568A1 (en) Novel heterocyclic compound
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
PH12019501027A1 (en) Therapeutic drug or prophylactic drug for diabetic nephropathy
MX2019012380A (es) Cristales de compuesto piranodipiridinico.
PH12016502247A1 (en) Carboxamide derivatives

Legal Events

Date Code Title Description
FG Grant or registration